Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model

Oncogene

Volumn 33, Issue 26, 2014, Pages 3392-3400

  Butinar, M ^a   Prebanda, M T ^a   Rajkovic J ^a   Jeric B ^a   Stoka, V ^a   Peters, C ^b   Reinheckel, T ^b   Kruger A ^c   Turk, V ^a,d   Turk, B ^a,d,e   Vasiljeva, O ^a,f  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b UNIVERSITY OF FREIBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins   (Slovenia)

^e UNIVERSITY OF LJUBLJANA   (Slovenia)

^f CytomX Therapeutics Inc   (United States)

Author keywords

breast cancer; cathepsin inhibitor; mouse model; oxidative stress; stefin

Indexed keywords

CATHEPSIN; CYSTATIN B; CSTB PROTEIN, MOUSE; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDE; IMMUNOSUPPRESSIVE AGENT; LEUCYL-LEUCINE-METHYL ESTER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER MODEL; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; IN VIVO STUDY; LYSOSOME; METASTASIS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SENSITIZATION; TUMOR CELL; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL MOTION; DISEASE COURSE; DRUG EFFECTS; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

MUS; POLYOMAVIRUS;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CATHEPSINS; CELL MOVEMENT; CELL PROLIFERATION; CYSTATIN B; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; DISEASE PROGRESSION; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LYSOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS;

EID: 84903639034     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.314     Document Type: Article

References (53)

1. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007; 6: 60-64.
2. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6: 764-775.
3. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases) - on the main stage of cancer? Cancer Cell 2004; 5: 409-410.
4. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007; 13: 387-403.
5. Turk B, Turk V. Lysosomes as 'suicide bags' in cell death: myth or reality? J Biol Chem 2009; 284: 21783-21787.
6. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 2012; 1824: 68-88.
7. Vasiljeva O, Turk B. Dual contrasting roles of cysteine cathepsins in cancer progression: Apoptosis versus tumour invasion. Biochimie 2008; 90: 380-386.
8. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006; 20: 543-556.
9. Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Muller S et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci USA 2010; 107: 2497-2502.
10. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 2006; 66: 5242-5250.
11. Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce JA. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res 2007; 67: 7378-7385.
12. Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J et al. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut 2012; 61: 877-884.
13. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004; 5: 443-453.
14. Mikhaylov G, Mikac U, Magaeva AA, Itin VI, Naiden EP, Psakhye I et al. Ferriliposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol 2011; 6: 594-602.
15. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25: 2465-2479.
16. Cirman T, Oresic K, Mazovec GD, Turk V, Reed JC, Myers RM et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem 2004; 279: 3578-3587.
17. Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of Bid and antiapoptotic Bcl-2 homologues. J Biol Chem 2008; 283: 19140-19150.
18. Stoka V, Turk V, Turk B. Lysosomal cysteine cathepsins: signaling pathways in apoptosis. Biol Chem 2007; 388: 555-560.
19. Turk B, Turk D, Salvesen GS. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des 2002; 8: 1623-1637.
20. Turk V, Stoka V, Turk D. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 2008; 13: 5406-5420.
21. Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 1997; 378: 141-150.
22. Alakurtti K, Weber E, Rinne R, Theil G, Haan G-Jd, Lindhout D et al. Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations. Eur J Hum Genet 2004; 13: 208-215.
23. Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996; 271: 1731-1734.
24. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem 2004; 385: 1017-1027.
25. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 2000; 6: 505-511.
26. Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet 1998; 20: 251-258.
27. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-961.
28. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ et al. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem 2001; 276: 3149-3157.
29. Bojic L, Petelin A, Stoka V, Reinheckel T, Peters C, Turk V et al. Cysteine cathepsins are not involved in Fas/CD95 signalling in primary skin fibroblasts. FEBS Lett 2007; 581: 5185-5190.
30. Lehtinen MK, Tegelberg S, Schipper H, Su H, Zukor H, Manninen O et al. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J Neurosci 2009; 29: 5910-5915.
31. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004; 53: 209-219.
32. Rygiel TP, Mertens AE, Strumane K, van der Kammen R, Collard JG. The Rac activator Tiam1 prevents keratinocyte apoptosis by controlling ROS-mediated ERK phosphorylation. J Cell Sci 2008; 121: 1183-1192.
33. Repnik U, Turk B. Lysosomal-mitochondrial cross-talk during cell death. Mitochondrion 2010; 10: 662-669.
34. Goldman R, Kaplan A. Rupture of rat liver lysosomes mediated by L-amino acid esters. Biochim Biophys Acta 1973; 318: 205-216.
35. Uchimoto T, Nohara H, Kamehara R, Iwamura M, Watanabe N, Kobayashi Y. Mechanism of apoptosis induced by a lysosomotropic agent, L-Leucyl-L-Leucine methyl ester. Apoptosis 1999; 4: 357-362.
36. Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, Krüger A et al. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 2008; 27: 4191-4199.
37. Antunes F, Cadenas E, Brunk UT. Apoptosis induced by exposure to a low steadystate concentration of H2O2 is a consequence of lysosomal rupture. Biochem J 2001; 356: 549-555.
38. Ishisaka R, Utsumi K, Utsumi T. Involvement of lysosomal cysteine proteases in hydrogen peroxide-induced apoptosis in HL-60 cells. Biosci Biotechnol Biochem 2002; 66: 1865-1872.
39. Takahashi T, Kitaoka K, Ogawa Y, Kobayashi T, Seguchi H, Tani T et al. Lysosomal dysfunction on hydrogen peroxide-induced apoptosis of osteoarthritic chondrocytes. Int J Mol Med 2004; 14: 197-200.
40. Yin L, Stearns R, Gonzalez-Flecha B. Lysosomal and mitochondrial pathways in H2O2-induced apoptosis of alveolar type II cells. J Cell Biochem 2005; 94: 433-445.
41. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001; 3: 323-327.
42. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991; 51: 794-798.
43. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995; 358: 1-3.
44. Datta K, Babbar P, Srivastava T, Sinha S, Chattopadhyay P. p53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress. Int J Biochem Cell Biol 2002; 34: 148-157.
45. Mao Y, Song G, Cai Q, Liu M, Luo H, Shi M et al. Hydrogen peroxide-induced apoptosis in human gastric carcinoma MGC803 cells. Cell Biol Int 2006; 30: 332-337.
46. Zuliani T, Denis V, Noblesse E, Schnebert S, Andre P, Dumas M et al. Hydrogen peroxide-induced cell death in normal human keratinocytes is differentiation dependent. Free Radic Biol Med 2005; 38: 307-316.
47. Kariya S, Sawada K, Kobayashi T, Karashima T, Shuin T, Nishioka A et al. Combination treatment of hydrogen peroxide and X-rays induces apoptosis in human prostate cancer PC-3 cells. Int J Radiat Oncol Biol Phys 2009; 75: 449-454.
48. Kopitar-Jerala N, Schweiger A, Myers RM, Turk V, Turk B. Sensitization of stefin B-deficient thymocytes towards staurosporin-induced apoptosis is independent of cysteine cathepsins. FEBS Lett 2005; 579: 2149-2155.
49. Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, Yang E et al. Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death Differ 2010; 17: 1354-1367.
50. Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res 2009; 15: 1024-1031.
51. Yu W, Liu J, Shi MA, Wang J, Xiang M, Kitamoto S et al. Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice. PLoS ONE 2010; 5: e13973.
52. Kuopio T, Kankaanranta A, Jalava P, Kronqvist P, Kotkansalo T, Weber E et al. Cysteine proteinase inhibitor cystatin A in breast cancer. Cancer Res 1998; 58: 432-436.
53. Turk B, Turk D, Turk V. Protease signalling: the cutting edge. EMBO J 2012; 31: 1630-1643.